Lorazepam—Efficacy, side effects, and rebound phenomena

  title={Lorazepam—Efficacy, side effects, and rebound phenomena},
  author={Martin B. Scharf and Judith A. Jacoby},
  journal={Clinical Pharmacology \& Therapeutics},
  • M. ScharfJ. Jacoby
  • Published 1 February 1982
  • Psychology, Medicine
  • Clinical Pharmacology & Therapeutics
Lorazepam, 4 mg, was evaluated in an 18‐night sleep‐laboratory study involving five insomniac subjects. Hypnotic effectiveness and effects on sleep stages and related parameters were assessed. Placebo was given on baseline nights 1 to 4, lorazepam on nights 5 to 11, and placebo was given again on withdrawal nights 12 to 18. Subjective and objective data clearly demonstrated that lorazepam was effective for both inducing and maintaining sleep. Sleep latency was reduced from a baseline value of… 

Comparison of Lorazepam and Flurazepam as Hypnotic Agents in Chronic Insomniacs

Both lorazepam 2 mg at bedtime and flurazepams 30 mg atBedtime were found to be effective and safe for treating chronic insomnia, as measured by parameters of sleep and daytime functioning.

Rebound Insomnia and Elimination Half‐Life: Assessment of Individual Subject Response

Previous reports using group mean values that demonstrate a frequent, immediate, and intense degree of rebound insomnia following abrupt withdrawal of relatively rapidly eliminated hypnotic drugs and an infrequent, delayed, and milder degree of sleep difficulty following withdrawal of slowly eliminated drugs are confirmed.

Rebound insomnia after hypnotic withdrawal in insomniac outpatients

The results show that pill discontinuation itself may worsen sleep and daytime well-being in the sense of a rebound phenomenon and indicates that a deterioration of sleep after drug withdrawal is not apparent during a few days but may last for longer periods in some patients and is modified by marked night-to-night variations.

Effects of lorazepam and its withdrawal on sleep, performance, and subjective state

Polysomnographic data and subjective reports indicated hypnotic efficacy in terms of sleep initiation and maintenance and there was some evidence of rebound insomnia after drug withdrawal, although it was not evident from all measures.

Quazepam and temazepam: Effects of short‐ and intermediate‐term use and withdrawal

Although temazepam was effective for maintaining sleep with short‐term use, there was rapid development of tolerance for this effect with intermediate‐ term use, and quazEPam had carryover effectiveness.

Comparison of short and long half‐life benzodiazepine hypnotics: Triazolam and quazepam

The 0.25 mg dose of triazolam, which is being prescribed increasingly, has a profile of side effects that is similar to that of the 0.5 mg dose, and is associated with sleep and mood disturbances whereas quazepam exerted carryover effectiveness.

Ceiling and floor effects in sleep research.

The results show powerful CF influences on sleep responses to hypnotics and exercise and suggest a need for comparing these treatments in poor sleepers.

Placebo‐controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety

Both the oral and sublingual lorazepam produced a significant anxiolytic effect; there was no statistically significant difference between the therapeutic effectiveness of the two forms of lorzepam.

Clorazepate and lorazepam: clinical improvement and rebound anxiety.

Some patients, however, experienced rebound anxiety, which appeared to be more intense and occurred earlier when placebo was substituted for a benzodiazepine with a short half-life than for one with a long half- life (clorazepate).

Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment.

In this double-blind, placebo-controlled study, 16 patients whose benzodiazepine was withdrawn abruptly were worse than 13 who had received placebo in terms of change in mean anxiety scores from the pretreatment level.



Anxiety and sleep after fosazepam.

Fosazepam administration improved subjective sleep quality, sleep was less broken, slow wave sleep stages 3 and 4 diminished in duration and so did REM sleep, suggesting action of a long half-life metabolite.

Hypnotic efficacy of lorazepam and flurazepam

In a double‐blind crossover study involving 15 insomniac subjects, the hypnotic efficacy of lorazepam, 2 and 4 mg, was compared with flurazepam, 15 and 30 mg, and placebo. Five subjective measures

Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines.

Rebound insomnia occurred following withdrawal of triazolam, nitrazepam, and flunitsepam after they had been given in only single, nightly doses for short periods, attributed to the short and intermediate half-lives of these drugs.

Lorazepam versus Glutethimide as a Sleep‐Inducing Agent for the Geriatric Patient

ABSTRACT: The safety of lorazepam was compared with that of a standard drug, glutethimide, in 50 chronically ill geriatric patients. Repeated physical examinations, laboratory determinations and

A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects.

Techniques of recording, scoring, and doubtful records are carefully considered, and Recommendations for abbreviations, types of pictorial representation, order of polygraphic tracings are suggested.

Comparative metabolism of lorazepam in man and four animal species.

The urinary route of excretion predominates in man, dog, cat, rat and miniature swine while in the rat the bulk of the drug-related material is eliminated with the feces as a consequence of biliary excretion.

Benzodiazepines in Clinical Practice

This ebooks is under topic such as guidelines for the use of benzodiazepines in office safe & effective use ofBenzodiazepine in clinical practice management of benzdiazepinesin medication-assisted treatment clinical practice guide lines for management of Benzodiazepin dependence prescribing and tapering clinical practice.

Rebound insomnia: a new clinical syndrome.

Rebound insomnia followed the withdrawal of three benzodiazepine hypnotic drugs, each of which had been administered in a single nightly dose for only short-term periods. The intense worsening of

Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam.

Biotransformation to a pharmacologically inactive glucuronide metabolite appeared to be the major mechanism of lorazepam clearance and its metabolites in body fluids were determined by appropriate analytic techniques.

Multiple Comparisons among Means

Abstract Methods for constructing simultaneous confidence intervals for all possible linear contrasts among several means of normally distributed variables have been given by Scheffe and Tukey. In